ArticleMolecular and cellular biology1994
PML, a growth suppressor disrupted in acute promyelocytic leukemia.
Article in Molecular and cellular biology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed, 292 citations in OpenAlex.
- m7G RNA methylation in cancer: Effect, mechanism and clinical application.Clinical and translational medicine · 2025Review
- PML Recruits TET2 to Regulate DNA Modification and Cell Proliferation in Response to Chemotherapeutic Agent.Cancer research · 2018Article
- PML(NLS¯) protein: A novel marker for the early diagnosis of acute promyelocytic leukemia.Molecular medicine reports · 2017Article
- TRIMming p53's anticancer activity.Oncogene · 2016Review
- HO-1, RET and PML as possible markers for risk stratification of acute myelocytic leukemia and prognostic evaluation.Oncology letters · 2015Article
- Critical role of presenilin-dependent γ-secretase activity in DNA damage-induced promyelocytic leukemia protein expression and apoptosis.Cell death and differentiation · 2013Article
- Emerging Cellular Functions of Cytoplasmic PML.Frontiers in oncology · 2013Article
- PML(NLS(-)) inhibits cell apoptosis and promotes proliferation in HL-60 cells.International journal of medical sciences · 2013Article
- Nuclear domain 10-associated proteins recognize and segregate intranuclear DNA/protein complexes to negate gene expression.Virology journal · 2012Article
- The organic arsenic derivative GMZ27 induces PML-RARα-independent apoptosis in myeloid leukemia cells.Anticancer research · 2012Article
- Sp100 as a potent tumor suppressor: accelerated senescence and rapid malignant transformation of human fibroblasts through modulation of an embryonic stem cell program.Cancer research · 2010Article
- SENP3-mediated de-conjugation of SUMO2/3 from promyelocytic leukemia is correlated with accelerated cell proliferation under mild oxidative stress.The Journal of biological chemistry · 2010Article
- PML3 Orchestrates the Nuclear Dynamics and Function of TIP60.The Journal of biological chemistry · 2009Article
- Acetylation of PML is involved in histone deacetylase inhibitor-mediated apoptosis.The Journal of biological chemistry · 2008Article
- Auranofin promotes retinoic acid- or dihydroxyvitamin D3-mediated cell differentiation of promyelocytic leukaemia cells by increasing histone acetylation.British journal of pharmacology · 2008Article
- Review
- Ability of the human cytomegalovirus IE1 protein to modulate sumoylation of PML correlates with its functional activities in transcriptional regulation and infectivity in cultured fibroblast cells.Journal of virology · 2004Article
- PML nuclear bodies and apoptosis.Oncogene · 2004Review
- Repression of PML nuclear body-associated transcription by oxidative stress-activated Bach2.Molecular and cellular biology · 2004Article
- Myeloid leukemia with promyelocytic features in transgenic mice expressing hCG-NuMA-RARalpha.Oncogene · 2004Article
42 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The nonrandom chromosomal translocation t(15;17)(q22;q21) in acute promyelocytic leukemia (APL) juxtaposes the genes for retinoic acid receptor alpha (RAR alpha) and the putative zinc finger transcription factor PML. The breakpoint site encodes fusion protein PML-RAR alpha, which is able to form a heterodimer with PML. It was hypothesized that PML-RAR alpha is a dominant negative inhibitor of PML. Inactivation of PML function in APL may play a critical role in APL pathogenesis. Our results demonstrated that PML, but not PML-RAR alpha, is a growth suppressor. This is supported by the following findings: (i) PML suppressed anchorage-independent growth of APL-derived NB4 cells on soft agar and tumorigenicity in nude mice, (ii) PML suppressed the oncogenic transformation of rat embryo fibroblasts by cooperative oncogenes, and (iii) PML suppressed transformation of NIH 3T3 cells by the activated neu oncogene. Cotransfection of PML with PML-RAR alpha resulted in a significant reduction in PML's transformation suppressor function in vivo, indicating that the fusion protein can be a dominant negative inhibitor of PML function in APL cells. This observation was further supported by the finding that cotransfection of PML and PML-RAR alpha resulted in altered normal cellular localization of PML. Our results also demonstrated that PML, but not PML-RAR alpha, is a promoter-specific transcription suppressor. Therefore, we hypothesized that disruption of the PML gene, a growth or transformation suppressor, by the t(15;17) translocation in APL is one of the critical events in leukemogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.